Prevalence of hypomagnesemia and hypokalemia in patients with st elevation mi and its relationship with occurrence of arrhythmias by Devanath, D
“PREVALENCE OF HYPOMAGNESEMIA &
HYPOKALEMIA IN PATIENTS WITH STEMI & ITS
RELATIONSHIP WITH OCCURRENCE OF
ARRHYTHMIAS”
A DISSERTATION SUBMITTED TO THE TAMILNADU
Dr. MGR MEDICAL UNIVERSITY
CHENNAI
In partial fulfilment of the Regulations
for the award of the Degree of
M.D.  (GENERAL MEDICINE) BRANCH-I
DEPARTMENT OF GENERAL MEDICINE
TIRUNELVELI MEDICAL COLLEGE
TIRUNELVELI
MAY 2018
CERTIFICATE BY THE GUIDE
This is to certify that the dissertation entitled “PREVALENCE OF
HYPOMAGNESEMIA & HYPOKALEMIA IN PATIENTS WITH STEMI
& ITS RELATIONSHIP WITH OCCURRENCE OF ARRHYTHMIAS” is
a bonafide research work done by Dr.DEVANATH.D, Postgraduate M.D.
student in Department of General Medicine, Tirunelveli Medical College &
Hospital, Tirunelveli, in partial fulfilment of the requirement for the degree of
M.D. in  GENERAL MEDICINE.
Date:
Place: Tirunelveli
Dr. S.ALAGESAN M.D.D.M.,
Professor, Department of General Medicine,
Tirunelveli Medical College,
Tirunelveli
CERTIFICATE BY THE HEAD OF THE DEPARTMENT
This is to certify that the dissertation entitled “PREVALENCE OF
HYPOMAGNESEMIA & HYPOKALEMIA IN PATIENTS WITH STEMI
& ITS RELATIONSHIP WITH OCCURRENCE OF ARRHYTHMIAS” is
a bonafide research work done by Dr.DEVANATH.D, Postgraduate M.D.
student in Department of General Medicine, Tirunelveli Medical College &
Hospital, Tirunelveli, under the guidance of Dr.S.ALAGESAN M.D.D.M.,
Professor, Department of Medicine, Tirunelveli Medical College & Hospital,
Tirunelveli, in partial fulfilment of the requirements for the degree of M.D. in
GENERAL MEDICINE.
Date:
Place: Tirunelveli
Dr.A.S. MOHAN, M.D.,
Professor and HOD of General Medicine,
Department of General Medicine,
Tirunelveli Medical College,
Tirunelveli
CERTIFICATE BY THE HEAD OF THE INSTITUTION
This is to certify that the dissertation entitled “PREVALENCE OF
HYPOMAGNESEMIA & HYPOKALEMIA IN PATIENTS WITH STEMI
& ITS RELATIONSHIP WITH OCCURRENCE OF ARRHYTHMIAS” is
a bonafide and genuine research work carried out by Dr.DEVANATH.D under
the guidance of Dr.S.ALAGESAN M.D.D.M., Professor, Department of
General Medicine and HOD, Department of General Medicine, Tirunelveli
Medical College, Tirunelveli.
Date:
Place: Tirunelveli
Dr.K.Sithy Athiya Munarvah,MD., (Patho)
DEAN
Tirunelveli Medical College,
Tirunelveli
COPYRIGHT
DECLARATION BY THE CANDIDATE
I hereby declare that dissertation entitled “PREVALENCE OF
HYPOMAGNESEMIA & HYPOKALEMIA IN PATIENTS WITH STEMI
& ITS RELATIONSHIP WITH OCCURRENCE OF ARRHYTHMIAS” is
a bonafide and genuine research work carried out by me under the guidance of
Dr.S.ALAGESAN M.D.D.M., Professor, Department of General Medicine,
Tirunelveli Medical College, Tirunelveli.
The Tamil Nadu Dr.M.G.R. Medical University, Chennai shall have the
rights to preserve, use and disseminate this dissertation in print or electronic
format for academic/research purpose.
Date:
Place:Tirunelveli
Dr.Devanath.D,MBBS.,
Postgraduate in General Medicine,
Department of General Medicine,
Tirunelveli Medical College,
Tirunelveli
ACKNOWLEDGEMENT
I am obliged to record my immense gratitude to Dr.Sithy Athiya
Munarvah, Dean, Tirunelveli Medical College Hospital for providing all the
facilities to conduct the study.
I express my deep sense of gratitude and indebtedness to my respected
teacher and guide Dr.S.ALAGESAN M.D.D.M., Professor and A.S.MOHAN
HOD, Department of General Medicine, Tirunelveli Medical College,
Tirunelveli, whose valuable guidance and constant help have gone a long way in
the preparation of this dissertation.
I am thankful to my former chief professor Dr.M. PAUL RAJ M.D., for
his guidance throughout the study.
I am also thankful to Assistant Professors Dr.S.Jawahar M.D.,
Dr.T.Vinotha M.D., Dr. Jasmine Kalyani M.D.D.M., S.RajaGopal M.D., for
their help.
I express my thanks to all Professors, Associate Professors, Assistant
Professors, Staff members of the Department of General Medicine and all my
Postgraduates colleagues and friends for their help during my study and
preparation of this dissertation and also for their co-operation.
I am sincerely indebted to Professor Dr. J.M.RAVICHANDRAN
EDWIN M.D, D.M and Dr. T.VISWANATHAN M.D. D.M for his valuable
advice and guidance throughout the study without which this study would not
have happened.
Lastly, I express my thanks to my patients without whom this study would
not have been possible.
CONTENTS
SL. NO. TOPIC PAGE NO.
1. INTRODUCTION 1
2. AIM AND OBJECTIVES 3
3. REVIEW OF LITERATURE 4
4. MATERIALS AND METHODS 33
5. OBSERVATION & RESULTS 41
6. DISCUSSION 73
7. SUMMARY 81
8. CONCLUSION 82
9. BIBLIOGRAPHY
10. ANNEXURE I - PROFORMA
11. ANNEXURE II - CONSENT FORM
12. ANNEXURE III - MASTER CHART

CERTIFICATE - II
This is certify that this dissertation work title “PREVALENCE OF
HYPOMAGNESEMIA & HYPOKALEMIA IN PATIENTS WITH STEMI &
ITS RELATIONSHIP WITH OCCURRENCE OF ARRHYTHMIAS” of the
candidate Dr.DEVANATH.D with registration Number 201511352 for the award
of M.D. in the branch of GENERAL MEDICINE. I personally verified the
urkund.com website for the purpose of plagiarism check. I found that the uploaded
thesis file contains from introduction to conclusion page and result shows 1
percentage of plagiarism in the dissertation.
Guide & Supervisor sign with Seal.

1INTRODUCTION
Ischemic heart disease causes more deaths and disability and incurs
greater economic costs than any other illness in the developed world. It is the
most common serious, chronic life - threatening debilitating disease in the
world. Genetic factors, a high fat and energy rich diet, smoking and a
sedentary life style are associated with the emergence of IHD.
With urbanization in countries with emerging economies and growing
middle class, elements of the energy rich western diet are being adapted. As a
result, the prevalence of risk factors for IHD and the prevalence of IHD itself
are increasing rapidly. Population subgroups that appear to be particularly
affected are men in South Asian countries especially India and the Middle
East.
Obesity, insulin resistance and type 2 diabetes are increasing and are
powerful risk factors of IHD. There is a widespread research not only for the
understanding of known risk factors but also to identify new risk factors and
prognosis indicators. Those are C- reactive proteins, levels, blood uric acid
levels, blood magnesium levels and potassium levels. Serum magnesium and
potassium levels are in the spotlight, since it leads to life threatening
arrhythmias
2This thesis titled “Prevalence of Hypomagnesaemia and
Hypokalemia in acute STEMI and its relationship with the occurrence of
arrhythmias” is an attempt to estimate the serum levels of magnesium and
potassium in patients admitted in our ICCU department, Tirunelveli
Government Medical College with AMI. Previous studies did have showed
low magnesium levels in patients with acute MI and are a poor prognostic
factor since it is associated with threatening arrhythmias. The prophylactic
magnesium supplementation is still a controversial topic. This study is an
attempt to establish the relationship between the occurrence of arrhythmias
and hypokalemia and hypomagnesaemia and whether magnesium
supplementation is warranted.
This study starts with the aims and objective of the study, followed by a
review of literature regarding ischemic heart disease, magnesium and heart,
various types of arrhythmias. Then followed by discussion of the methods and
materials used and discussion regarding the observation and results followed
by conclusion and summary of the study.
3AIMS AND OBJECTIVES
1. To estimate the prevalence of hypomagnesaemia and hypokalemia in
patients who present with AMI- STEMI.
2. To determine whether the hypomagnesaemia and hypokalemic patients
are at risk for ventricular arrhythmias or other complications.
4REVIEW OF LITERARURE
Ischemic heart disease is a condition in which there is an inadequate
supply of blood and oxygen to a portion of the myocardium. It typically
occurs when there is an imbalance between myocardial oxygen supply and
demand. The most common cause of myocardial ischemia is atherosclerotic
disease of an epicardial coronary artery which causes reduction in blood flow
and inadequate
tissue perfusion.
Patient with ischemic heart disease fall into two large groups:
1. Coronary artery disease, which presents as stable angina.
2. Acute myocardial Infarction.
Acute myocardial Infarction:
Definition:
A 2007 expert consensus document redefined Acute MI as the
detection of a rise or and fall in cardiac troponin with at least one value above
the 99th URL utilizing an array with <10% coefficient of variation at the level
of detection together with evidence of ischemia. [1]
5Ischemia was defined as any symptom of ischemia,
electrocardiographic changes suggestive of a new ischemia with the
development of pathologic ‘q’waves on ECG and an imaging evidence of
infarction [2]
Clinical classification of different types of Myocardial Infarction:
Clinical spectrum of Acute MI:
 UA- Unstable Angina
 NSTEMI- Non ST Elevation Myocardial Infarction
 STEMI- ST Elevation Myocardial Infarction
STEMI:
Myocardial infarction is almost due to thrombus formation at the site of
an atherosclerotic plaque erosion or rupture. Thrombus completely occludes
the vascular lumen which causes the characteristic ST elevation pattern in
ECG.
CLINICAL DIAGNOSIS:
A) Signs & symptoms:
61) A crushing sub sternal chest pain typically more severe which is
described as a constricting sensation with frequent radiation to
the left arm, neck, back, jaw with an impending sense of doom.
2) Associated symptom:
Diaphoresis, dyspnea,   palpitation, light
headedness, or giddiness. Nausea and vomiting may
be present.
B) Physical examination:
It doesn’t add much to the diagnosis of MI, but is
extremely important in excluding other diagnoses that may
mimic MI.
DIAGNOSIS:
ECG is a pivotal diagnostic and triage tool because it is at the centre of
the decision pathway for management.
There is ST segment elevation initially in two or more contiguous leads,
followed by loss of R wave amplitude in the next fours. T wave inversion
occurs within a few days followed by a well-established q wave over some
days to weeks.
7BIOMARKERS:
Biomarkers are Creatinine kinase – cardio specific isoform (CK-MB)
and Troponin–T and Troponin-I.
CPK-MB starts to rise at six hours and peaks at 12 hours and falls to
normal within 3 days. Cardiac troponins are elevated after six hours and
remain elevated up to two weeks.[3]
It helps in differentiating NSTEMI from UA. They are also important in
assessing the progression of STEMI.
8Figure showing the relationship between the myocyte injury and
elevation of cardiac biomarkers like Troponin-I and T, creatinine
phosphokinase and its concentration in serum in relationship to days after the
onset of MI.
9MANAGEMENT:
General principles:
The patient is admitted in an Intensive Coronary Care Unit. Nasal
oxygen should be given. IV access should be obtained immediately.
Aspirin is essential in the management of patients with suspected
STEMI and is effective across the entire spectrum of Acute Coronary
Syndromes. It is given in a dose of 160-325 mg tablet in the ED, followed by
75-162mg daily oral administration along with 40-80mg Atorvastatin.
Reperfusion therapy:
It is achieved with either fibrinolytic therapy or primary percutaneous
intervention or bypass grafting
Fibrinolysis:
If no contraindications are present, fibrinolytic therapy should be
initiated with 30 minutes of presentation. The principal goal of fibrinolysis is
prompt restoration of full coronary arterial patency.
Fibrinolytic agents:
 tPA- tissue Plasminogen Activator
 streptokinase
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 Tenecteplase(TNK)
 Reteplase(rPA)
PRIMARY PERCUTANEOUS CORONARY INTERVENTION (PCI):
PCI, usually angioplasty and/or stenting without preceding fibrinolysis,
referred to as Primary PCI is effective in restoring perfusion in STEMI.
CORONARY ARTERY BYPASS GRAFTING:
It is directed at the epicardial vessel, including the culprit lesion or
lesions and future culprits, proximal to the insertion of a vein graft, a
difference that may account for the superiority of CABG.
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ADJUNCTIVE THERAPIES:
Nitrates:
In relieving pain and the treatment of Acute left ventricular Failure.
Beta blockers:
In reducing pain and in preventing arrhythmias during the first 12
hours.
ACE inhibitors:
It prevents Left Ventricular remodeling.
Morphine:
2 to 4 mg IV can be used for refractory chest pain that is not responsive
to nitroglycerin. Adequate analgesia decreases levels of circulating
catecholamines and reduces myocardial oxygen consumption.[4]
COMPLICATIONS FOLLOWING MI:
 Recurrent chest pain
 Acute pericarditis
 Dressler’s syndrome
 Arrhythmias
 Cardiogenic shock
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 Heparin Induced Thrombocytopenia   (HIT).
Mechanical complications:
 LV aneurysm
 Ventricular Pseudo aneurysm
 Free wall rupture
 Papillary muscle rupture
 Ventricular septal rupture
 Ischemic MR (MR)
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ARRYTHMIAS:
The incidence of arrhythmias after STEMI is higher in patients seen
early after the onset of symptoms.
Since most deaths from arrhythmias occur during the first few hours
after infarction, the effectiveness of treatment directly relates to the speed
with which patients come under medical observation.
The mechanisms responsible for infarction related arrhythmias include
autonomic nervous system imbalance, electrolyte disturbances, ischemia and
slowed conduction in zones of ischemic myocardium.
EXACERBATING CONDITIONS:
 Electrolyte disturbances. (Hypokalemia and hypomagnesaemia)
 Hypoxia
 Acidosis
 Adverse drug effects. ( Digoxin and Quinidine)
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TYPES OF ARRHYTHMIAS:
1) INTRAVENTRICULAR CONDUCTION DELAY:
The left anterior fascicle is most commonly affected because of isolated
coronary blood supply.
Bi-Fascicular and Tri-fascicular block may progress to complete heart
block and other rhythm disturbances.
Treatment: None.
2) SINUS BRADYCARDIA:
Sinus Bradycardia is common in patients with RCA infarcts.
In the absence of hypotension or significant ventricular ectopic,
observation is indicated.
15
Treatment: None
Atropine 0.5/temporary pacing mg
3) AV BLOCK:
Usually temporary. If there is hypotension or second/ third degree
block, a temporary pacemaker should be considered.
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4) SINUS TACHYCARDIA:
Sinus tachycardia is common in patients with acute MI and is often due
to enhanced sympathetic activity resulting from pain, anxiety, hypervolemia,
heart failure or fever.
Persistent ST suggests poor underlying ventricular function and is
associated with excess mortality.
Treatment: None
5) ATRIAL FIBRILLATION:
Atrial fibrillation and flutter are observed in up to 20% of patients with
Acute MI. It is usually transient. If severe enough to cause hypotension, DC
cardio-conversion is required.
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6) ACCELERATED JUNCTIONAL RHYTHM:
It occurs in conjunction in inferior wall MI and also seen in Digoxin
intoxication.
7) VPC:
It is the common in the course of acute MI. Prophylactic treatment with
lidocaine or other anti-arrhythmic has been associated with increased overall
mortality and is not recommended.
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8) AIVR:
It is commonly seen within 48 hours of successful reperfusion and is
not associated with an increased incidence of adverse outcomes.
If hemodynamically unstable, sinus activity may be restored with
atropine or temporary atrial pacing.
9) VENTRICULAR TACHYCARDIA (VT):
Non Sustained Ventricular Tachycardia (NSVT <30 seconds) is
common in the first 24 hours after MI and is only associated with increased
mortality when occurring late in the post MI course.
Sustained VT >30 seconds, during the first 48 hours, after acute MI and
is associated with increased in hospital mortality.
19
Treatment: Cardio-version for sustained VT. Lidocaine or amiodarone for
24-48 hours.
10) VENTRICULAR FIBRILLATION (VF):
VF occurs in 5% of patients with acute MI in the early hours and is life
threatening.
Treatment: Unsynchronized Cardio-version.
Lidocaine or amiodarone for 24-48 hours.
MAGNESIUM:
Magnesium is the most prevalent intracellular divalent cation and the
second most prevalent cation in the body [5]. The normal adult body content is
approximately 20-25 g and its distribution is between 60 to 70% in bones, 25
to 30% in muscles, 6 to 8% in soft tissues and 1% in the extra cellular fluid. In
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children about one-third of Mg resides on the surface of bone probably
serving as a reservoir to maintain the extracellular concentration but in adults
this mostly an integral part of bone crystal structure [6]. In the plasma, 55% of
Mg is ionized or free, 15% is complexed to anions and the rest is bound to
protein, chiefly albumin. Mg is contained within all intracellular
compartments. It is principally bound to ATP (80 to 90%) and other
negatively charged molecules. Total cellular Mg ranges from 5-20 mM
depending on the metabolic activity of a cell. Mg is actively transported into
and out of cells and is influenced by various hormonal and pharmacological
factors which perhaps regulate the intracellular Mg 2+ concentration[7]
FUNCTIONS:
The physiological role of Mg is principally related to enzyme activity;
over 300 enzyme systems particularly Kinases are dependent on the presence
of this Cation. This includes all enzyme utilizing ATP, they requires Mg for
substrate formation [8]. Intracellular free Mg 2 + also acts as an allosteric
activator of enzyme action including critical enzyme systems such as
adenylate cyclase, phospholipase C and Na/K-ATPase. It is established that
Mg is critical for a number of cellular functions including oxidative
phosphorylation, glycolysis, DNA transcription and protein synthesis and the
clinical complications of Mg depletion are may be due to perturbation of Mg-
21
requiring enzyme systems. Magnesium is fundamentally required for the
energy transfer reactions involving high energy compounds like ATP and
creatine phosphate and thus muscle contraction. Thus, it plays vital role in
heart and skeletal system function.
Transport of potassium and calcium across the plasma membrane may
also require the presence of Mg. Mg has been also termed as nature's
physiologic calcium channel blocker. During Mg depletion, intracellular
potassium decreases while calcium and sodium increase. In view of close
association of occurrence and functions of Ca and Mg, there is evidence of
mutually synergistic as well as contraindicative roles of these two divalent
anions, particularly in bone health and hypertension.
MAGNESIUM METABOLISM:
Magnesium is widely distributed in foods. As it is the metal ion in
chlorophyll, plant products that form major source of Magnesium. Legumes
and cereals are good source of Magnesium. Animal products also contain
sufficient quantity [9]. Efficient mechanisms in both the gastrointestinal tract
and the kidney closely regulate Mg homeostasis. Though it is absorbed along
the entire intestinal tract, it appears to be most efficiently absorbed in the
distal small bowel. In the intestine, an active Mg-transport system accounts
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for greater fractional absorption at low dietary intake while at high dietary
intakes Mg absorption occurs at a lower fractional absorption rate and is due
to a passive absorption[10]. At a normal dietary Mg intake of approximately
300 to 350 mg/day, fractional absorption is 30 to 50%. This variation may be
due to the presence of other nutrients interacting with Mg in the gut including
high dietary fiber, phytate, oxalate, phosphate and dietary protein diets of <30
g/day which reduce Mg absorption by binding the cation or hindering
absorption.
The kidney most closely regulates Mg metabolism. There exists a
threshold of filtered Mg which is close to the normal plasma Mg
concentration. Excessive Mg, either dietary or parenterally administered, is
almost totally excreted. In contrast, at the time of Mg deprivation, the kidney
avidly conserves Mg. Diet also affects renal Mg excretion, high sodium,
calcium and protein diets, caffeine as well as alcohol may increase renal Mg
excretion. The major site of Mg re-absorption is the thick ascending limb of
Henle, which handles about 65% of the filtered load. Re-absorption in the
proximal tubule, 20-30% of filtered load, is linked to sodium and water as
well as calcium transport. The mechanisms of Mg transport in the intestine
and kidney is still unclear.
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Despite early proposals for the existence of a specific hormonal control of
Magnesium homeostasis, no single endocrine factor that controls circulating
or urinary Magnesium has been identified. It has been described as the body's
'orphan ion', because of an apparent lack of a specific endocrine control
similar to that existing for calcium, sodium and potassium. A number of
hormones, including parathyroid hormone and calcitonin, vitamin D, insulin,
glucagon, antidiuretic hormone, aldosterone and sex steroids have been
reported to influence Magnesium balance, notwithstanding the possibility that
these may not be primary regulators of magnesium homeostasis. Recent
observations suggest that these hormones act through a common second
messenger, adenosine 3', 5'- cyclic mono-phosphate to enhance magnesium
transport and modulate magnesium excretion at that nephron site.
MAGNESIUM AND HEART:
The rate of total cardiovascular and sudden cardiac death is associated
inversely with Mg2+ content in drinking water i.e. water hardness.[11]
Also there is an association between death from Acute MI and a
reduced Mg2+ concentration, the mechanisms implicated are focal myocardial
necrosis, small  vessel changes and spatially heterogeneous prolongation of
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ventricular repolarization with induction of polymorphic VT occur in
association with Mg2+ deficiency in animal studies.
ACUTE MYOCARDIAL INFARCTION:
A transient decline in the serum Mg2+ concentration takes place in 6 to
46% patients with AMI and the concentration is normalized in two weeks.
The decline in the serum Mg2+concentration following AMI is probably
explained by a shift between magnesium compartments in the body. In this,
catecholamine over secretion plays a major role [12]. Catecholamine induced
lipolysis with aggregation of Mg2+ wit free-fatty acids leads to sequestration
of Mg2+ in adipocytes and explains partly the observed hypomagnesaemia [13].
The catecholamine effect is not unique to AMI but all acutely stressful
conditions may be accompanied by hypomagnesaemia.[14,15,16]
It has also been proposed that hypomagnesaemia and Mg2+ depletion
ante cede the development of myocardial infarction. In support of this
hypothesis, depressed myocardial Mg2+ concentrations have been reported in
patients who have died of MI.
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HEART FAILURE:
Hypomagnesaemia and Mg2+ depletion are frequently encountered in
patients with heart failure and the presence of low Mg2+ indicates a worse
prognosis than among patients with a normal Mg2+ status. Those patients with
heart failure had significantly reduced mononuclear cell Mg2+ levels and this
was independent of diuretic therapy. The patients with a low left ventricular
EF and ventricular arrhythmias had decreased tissue Mg2+ levels together with
increased QT interval depression.
Factors contributing to the genesis of hypomagnesaemia and Mg2+
depletion consist of:
neurohormonal activation and pharmacological treatment of the disease
(thiazide and loop diuretics)
Low cardiac output
Diminished renal flow
Activation of compensatory vaso-constrictive and volume expanding
mechanisms
1) Catecholamine excretion can cause hypomagnesaemia.
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2) Activation of RAAS can increase the renal excretion of Mg2+
indirectly.
3) Aldosterone and vasopressin induced fluid retention and consequent
expansion of the extracellular volume results in reduced Mg2+
absorption in PCT. Volume expansion also leads to intestinal edema
with reduced absorption of Mg2+.[17]
As Mg2+ is mandatory co-factor of Na2+-K+ ATPase, the
hyperaldosteronism induced cellular Na2+ accumulation and K+ loss are
insufficiently counter acted by this pump. Na2+/Ca2+ counter transport will be
increased leading to intracellular accretion of calcium. Calcium overload in
the failing heart may cause additional deterioration of ventricular pump and
trigger ventricular arrhythmias.[18]
CORONARY ARTERY DISEASE:
Magnesium depletion might leads to atherosclerosis. Depressed
myocardial Mg2+ levels have been found post-mortem in patients with
ischemic heart disease [19]. A low dietary magnesium intake correlates
significantly with the incidence of ischemic heart disease. Mg2+ deficiency
produces endothelial changes and constricts the coronary arteries. Intracellular
Mg2+ deficiency is also seen in patients with coronary artery disease.
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Evidence suggests that endothelial dysfunction may be the initiating
event in the atherosclerotic process that subsequently leads to clinical CAD
[20]
. Accordingly, there has been an on-going, aggressive search for therapeutic
choices suitable for reversal of endothelial dysfunction with the hope that such
intervention, if instituted early in the course of the disease, might prevent or
modify the subsequent risk of clinical disease and related cardiac
events. Magnesium, which is an inexpensive, natural, and relatively safe
element, has been shown in the present study to improve endothelial function
and thus may be justified as an adjuvant therapy for CAD patients. Further
studies, with larger populations, are needed to prove our findings
CARDIAC SURGERY:
Cardiac surgery where cardiopulmonary bypass is utilized leads to
postoperative decline in serum Mg2+ levels [21]. The proposed causes for the
decline in serum Mg2+ concentration following cardiac surgery are hemo
dilution, use of diuretics, secondary hypoaldosteronism, increased anabolic
activity and enhanced sympathetic activity.
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ELECHOPYSIOLOGICAL EFFECTS OF MAGNESIUM
The functions of magnesium and potassium are closely related.
Hypokalemia is almost always associated with hypomagnesaemia.
Hypomagnesaemia is present in 40% of patients with hypokalemia [22].
Hypokalemia can be corrected only if magnesium is replete [23].
Intracellular magnesium is a potent blocker of cardiac muscle cell
potassium channels. Potassium has a tendency to flow into the cell from the
ECF compartment. When an electrochemical gradient favours outward flow
of potassium, Mg2+ ions blocks this channel preventing the outward flow of
K+. Hence these channels acquire a property known as inward rectification.
Inward rectification is important in the maintenance of plateau phase of
cardiac muscle action potential [24].
Magnesium ions modulate the intracellular calcium levels in the
sarcoplasmic reticulum through L type calcium channels. When there is an
increase or decrease of magnesium ion levels, there is a corresponding
inhibition or enhancement of the calcium inflow. Thus Mg regulates the
calcium channel function and transmembrane calcium flow. Magnesium is
considered as nature’s physiological calcium blocker.
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The mechanisms by which magnesium enters the cell and how it gets
removed from the cell through a Na+ - Mg2+ exchange trans membrane
protein are not clearly identified.
Arrhythmia mechanisms suppressible by magnesium
Mechanisms of arrhythmias:
1. Re-entry enhanced
2. Automaticity
3. Triggered activity
After depolarization’s or EAD’s and delayed after depolarization’s
(DAD) play an important role in triggered activity. Afterdepolarization occur
during the course of repolarization. If it occurs during the phase 4 of action
potential, they are called as DAD. Early after depolarization’s can be stopped
by magnesium.
In vitro experimental studies suggest that tachycardia produced by these
mechanisms is terminated by addition of magnesium Though mechanisms
behind EAD and DAD are different, this is true.
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EAD is caused by enhanced Ca2+ inflow through L type Ca2+
channels. Contributory effects are made by Na+ ions flowing through non-
inactivating Na2+ channels. The emergence of EAD is helped by the
prolonged duration of action potential. EAD’s most commonly seen in the
mammalian heart purkinjie cells which have the longest duration of AP.
Bradycardia or any sinus pause, substances like quinidine, barium, aconite,
Bay K 8644 lengthen the duration of action potential.
Magnesium inhibits the inflow of Ca2+ ions. By this mechanism, it
suppresses the EAD that occur during the phase 2 or plateau phase of the AP.
It also influences the EAD’s that occur during the phase 3 of membrane
potential which are more negative than - 60 millivolts and are modulated by
sodium currents.
The classical example of an arrhythmia based on EAD’s is pause
dependent “torsade de pointes” ventricular tachycardia. It is associated with a
long QT interval which may be drug or toxic induced.
Delayed after depolarization’s can be thought of as a result of
oscillations of the resting membrane potential (RMP) of myocytes. These
cardiac myocytes may be overloaded with calcium ions or they have
decreased conductance of K+ ions. This leads to activation of non-selective,
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inward transient flow of cations. It also activates the Na+-Ca2+ exchanger.
DAD’s also induced by catecholamines, digitalis toxicity, caffeine,
theophylline, histamine, lysophosphatidyl choline. This triggers the activity
responsible for arrhythmias which is suppressed by magnesium [25].
Myocardial magnesium depletion enhances SA node automaticity.
Mg2+ supplementation has a negative chronotropic effect. It also prolongs the
PR interval by its action on the AV node. The proposed mechanism is it
lengthens the AV nose refractory period. It does node have any actions over
the His-purkinjie conducting system. It does not increase the refractory period
of the atrial myocardium or the ventricular myocardium.
ECG findings in magnesium deficiency include ST segment depression,
flattering of T wave and QT prolongation.
In hypomagnesaemia, there is Bradycardia as a result of negative
inotropic action. There is PR interval prolongation, intraventricular
conduction abnormalities. The QRS complex is widened. The T wave are
shaper and higher.
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Magnesium and hypokalemia:
Observations in humans and animals show that Mg depletion renders
the cell unable to retain K difference between intra- and extracellular space
and results in intracellular K depletion. This phenomenon occurs because the
Na/K pump action depends on Mg. The insufficient action of the Na/K pump
results in K depletion and intracellular Na accumulation. Furthermore the
kidney cannot retain potassium.
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MATERIALS AND METHODS
Type of study:
Study population:
Patients who are admitted in Intensive Coronary Unit and were
diagnosed as acute ST segment elevation myocardial infarction.
Total no of cases: 100
Diagnosis and investigation of the cases:
Diagnosis:
Patients who are admitted in ICCU with symptoms suggestive of AMI
were evaluated. A complete history was elicited from the patient and detailed
clinical examination was done. A standard twelve lead electrocardiogram was
done in all patients. It was then analyzed for the presence of acute ST
elevation myocardial infarction.
ECG CRITERIA:
1. New onset ST segment elevation more than 1mm in limb leads and or
more than 2 mm in precordial leads.
2. The ST segment elevation should be present in two or more leads.
3. The two or more leads should be contiguous with respect to each other.
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Continuous cardiac monitoring and standard 12 lead electrocardiogram was
done to identify any arrhythmias in the first 24 hours since admission.
INCLUSION CRITERIA:
1. All patients with definite evidence of acute coronary syndrome-STEMI as
diagnosed by chest pain<24 hrs., ECG, enzyme assays and ECHO.
2. All patients with definite evidence of arrhythmias as diagnosed by
Continuous Cardiac monitoring and standard ECG.
3. Significant arrhythmia’s causing hemodynamic instability, sustained
Palpitation, syncope.
EXCLUSION CRITERIA:
1. Use of loop and thiazide diuretics
2. Poor dietary intake/malnourished state.
3. Chronic diarrhea/ persistent vomiting.
4. Diabetic ketoacidosis
5 Malabsorption syndromes.
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PROCEDURE DONE
1. Informed consent is obtained from the patient for the study.
2. Around 3 ml of venous blood sample is collected from the patient.
3. The time interval between admission and sample collection did not
exceed 6 hours.
4. The sample was transferred to a plain tube without any anticoagulants.
5. Proper labeling was done.
6. The proforma for each patient was filled appropriately.
7. The sample was sent to the biochemistry laboratory.
8. It is separated into the serum and fibrin clot.
9. The sample was centrifuged at 2000 rpm for the separation serum from
the blood.
10.The serum obtained was estimated for its magnesium concentration
using
Colorimetric method.
11.Through continuous cardiac monitoring and standard ECG at regular
intervals, arrhythmias were identified.
A total of 100 patients who met the inclusion criteria were investigated for
the serum magnesium and potassium levels within six hours since admission
and overlooked for the presence of arrhythmias during the first 48 hours.
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Method for magnesium estimation:
Colorimetry:
The concentration of coloured solutes in a solution is determined by a
technique called colorimetry. A light of known wavelength and intensity is
passed through the coloured solution. After the light passes through the
solution there is a change in the wavelength and may be the intensity of the
light beam. These properties are detected by spectrophotometer. The change
in the property of the light emitted and detected is proportional to the intensity
of the colour in the solution. The intensity of the colour is directly
proportional to the concentration of the solute. Thus, indirectly we can
estimate the concentration of the dissolved compound.
Calmagite method:
It is a complex chemical compound. It becomes wine red in colour
when it combines with a metal ion like Mg2+ and blue in colour when it is not
combined with a metal ion.
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Structure:
Principle:
When magnesium combines with calmagite in the presence of an
alkaline medium it imparts a red colour. Calcium and protein interference is
eliminated by the addition of specific chelating agents and detergents. The
intensity of the colour formed is directly proportional to the concentration of
magnesium present in the sample.
Magnesium + calmagite                                    red coloured complex
(alkaline medium)
Normal reference values:
Serum:
Children: 1.5 to 2 mg/dl
Adults: 1.7 to 2.5 mg/dl
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CSF: 2.0 t0 3.0 meq/dl
Urine: 6.0 to 8.5 meq/dl
Sample material:
Serum free hemolysis. Magnesium is stable in plasma for 7 days at 2-8 degree
Celsius.
Procedure:
Wavelength/filter: 510 nm /green
Temperature: room temperature
Light path: 1 centimeter
Incubation time: 5 minutes
Linearity:
The procedure is linear up to 10 meq/l. the sample should be diluted with
distilled water if this value is exceeded. The assay should be repeated. The
value is corrected using an appropriate dilution factor.
Calculations:
Magnesium in meq/l = (Abs.T / Abs.S) *2
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SERUM POTASSIUM ESTIMATION:
Ion-selective electrode (ISE) methods use a glass ion-exchange
membrane for sodium and a valinomycin neutral-carrier membrane for
potassium measurement.
METHOD USED:
Ion- selective electrode.
SAMPLE:
Serum free from hemolysis.
Plasma and serum sodium and potassium are stable for at least 1 week
at room or refrigerator temperatures and for at least 1 year frozen. Urine
sodium and potassium are stable for at least 1 week at room temperature and
indefinitely if frozen.
There are two general types of ISE measurements made on clinical
samples. “Direct” potentiometric systems measure the ion activity in an
undiluted sample. “Indirect” ISE systems measure the ion activity in a
prediluted sample. Because ISE measurements determine the activity of an ion
in the water-volume fraction in which it is dissolved, “direct” measurements
are unaffected by conditions such as hyperproteinemia or hyperlipidemia,
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which alter the volume fraction of water in serum. However, “indirect”
methods are usually sensitive to this physiological effect because the dilution
step itself is based on total volumes, and after dilution, the volume occupied
by soluble serum molecules becomes insignificant with respect to the total
diluent volume.
NORMAL SERUM LEVELS:
3.5 to 5 meq/l.
URINE:
Potassium 25 to 125 mmol/24 hr.
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OBSERVATION & RESULTS
Age Distribution:
AGE(IN YEARS) NO OF  PATIENTS
< 40 9
41-50 23
51-60 31
61-70 25
> 70 12
Range- 34-77 years
Mean ± S.D = 57.65 ± 12.05
Most commonly patients were in 6th decade
9
23
31
25
12
< 40 41-50 51-60 61-70 > 70
AGE DISTRIBUTION
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SEX DISTRIBUTION:
SEX NO OF PATIENTS
MALE 83
FEMALE 17
MALE: FEMALE RATIO = 5.1:1
Acute myocardial infarction is most commonly seen in males. N=83
83%
17%
SEX DISTRIBUTION
MALE
FEMALE
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TYPE OF MYOCARDIAL INFARCTION
TYPE OF MI NO OF PATIENTS
AWMI 47
ALMI 2
ASMI 13
IWMI 17
IWMI/PWMI 19
IWMI/ASMI 2
AWMI (N = 47) IS MOST COMMON TYPE FOLLOWED BY IWMI WITH
PWMI
47
2
13
17 1
9
2
AWMI A LM I A SM I IWMI IWMI / PWMI IWMI /A SM I
TYPE OF MYOCARDIAL INFARCTION
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BLOOD PRESSURE
BLOOD PRESSURE NO OF PATIENTS
RECORDABLE 80
NOT RECORDABLE 20
20 % of the patients with AMI associated with arrhythmias presented with
hemodynamic instability.
80%
20%
BLOOD PRESSUYRE
RECORDABLE
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SYSTOLIC BLOOD PRESSURE
SYSTOLIC BP(N-80) NO OF PATIENTS PERCENTAGE
HIGH 26 32.50%
NORMAL 54 67.50%
AMONG PATIENTS FOR WHOM BP IS RECORDABLE 26 PATIENTS
(32.50%) HAS HIGH LEVEL
32%
68%
SYSTOLIC BP
HIGH
NORMAL
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DIASTOLIC BLOOD PRESSURE
DIASTOLIC BP (N=80) NO OF PATIENTS PERCENTAGE
HIGH 7 8.75%
NORMAL 73 91.25%
AMONG PATIENTS FOR WHOM BP IS RECORDABLE 7 PATIENTS
(9%) HAS HIGH LEVEL
9%
91%
DIASTOLIC BP
HIGH
NORMAL
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PULSE RATE
PULSE RATE NO OF PATIENTS
RECORDABLE 80
UNRECORDABLE 20
80
20
RECORDABLE UNRECORDABLE
PULSE RATE
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PULSE RATE(N-80) NO OF PATIENTS PERCENTAGE
HIGH 27 33.75%
NORMAL 40 50%
LOW 13 16.25%
27
40
13
0 5 10 15 20 25 30 35 40 45
HIGH
NORMAL
LOW
PULSE RATE
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ARRYTHMIA
ARRYTHMIA NO OF PATIENTS
PRESENT 76
ABSENT 24
76
24
P R E S ENT ABS ENT
ARRYTHMIA
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TYPE OF
ARRYTHMIA
NO OF PATIENTS
(N=76)
PERCENTAGE
VPC 19 25%
SINUS
TACHYCARDIA
21
27.6%
CHB/1°/2° BLOCK 6 7.9 %
VT 19 25%
SINUS
BRADYCARDIA
3
3.9%
RBBB 3 3.9%
LBBB 5 7.7%
VPC
SINUS
TACHYCARDIACHB/1°/2°
BLOCK
VT
SINUS
BRADYCARDIA
RBBB LBBB
TYPE OF ARRYTHMIA
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SERUM MAGNESIUM NO OF PATIENTS
NORMAL 59
LOW 41
59
41
NORMAL LOW
SERUM MAGNESIUM
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SERUM POTASSIUM NO OF PATIENTS
NORMAL 62
LOW 38
62
38
0
10
20
30
40
50
60
70
NORMAL LOW
SERUM POTASSIUM
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TREATMENT OF PATIENTS
MANAGEMENT NO OF PATIENTS
DC
SHOCK/THROMBOLYSIS
20
THROMBOLYSIS ALONE 80
20%
80%
MANAGEMENT
DC SHOCK/THROMBOLYSIS
THROMBOLYSIS ALONE
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SERUM MAGNESIUM
ARRYTHMIA
PRESENT ABSENT
LOW 35 6
NORMAL 41 18
MANN WHITNEY U TEST
P VALUE - 0.048
SIGNIFICANT
35
6
41
18
0
5
10
15
20
25
30
35
40
45
PRESENT ABSENT
ARRYTHMIA
SERUM MAGNESIUM LEVEL VS  ARRYTHMIA
LOW NORMAL
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TYPE OF
ARRYTHMIA
SERUM MAGNESIUM
MEAN STANDARDDEVIATION
VPC 1.75 0.27
SINUS
TACHYCARDIA 1.77 0.2
CHB/1°/2° BLOCK 1.63 0.2
VT 1.44 0.48
SINUS
BRADYCARDIA 1.6 0.1
RBBB 1.86 0.32
LBBB 1.78 0.28
NIL 1.81 0.25
VT HAS LOW MEAN SERUM MAGNESIUM WHICH IS
STATISTICALLY SIGNIFICANT WITH P VALUE OF 0.008
1.75 1.77 1.63
1.44
1.6
1.86 1.78 1.81
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
2
MEAN SERUM MAGNESIUM
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SERUM MAGNESIUM
TYPE OF
ARRYTHMIA LOW NORMAL
VPC 8 11
SINUS
TACHYCARDIA 6 15
CHB/1°/2° BLOCK 3 3
VT 13 6
SINUS
BRADYCARDIA 2 1
RBBB 1 2
LBBB 2 3
NIL 6 18
8 6
3
13 2
1 2 6
11 15
3
6 1
2 3 18
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
SERUM MAGNESIUM LEVEL VS TYPE
LOW NORMAL
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SERUM POTASSIUM ARRYTHMIAPRESENT ABSENT
LOW 34 4
NORMAL 42 20
MANN WHITNEY U TEST
P VALUE - 0.013
SIGNIFICANT
34
4
42
20
0
5
10
15
20
25
30
35
40
45
PRESENT ABSENT
SERUM POTTASIUM LEVEL VS ARRYTHMIA
LOW NORMAL
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TYPE OF
ARRYTHMIA
SERUM POTASSIUM
MEAN STANDARDDEVIATION
VPC 3.7 0.54
SINUS
TACHYCARDIA 3.7 0.4
CHB/1°/2° BLOCK 3.9 0.51
VT 2.7 0.54
SINUS
BRADYCARDIA 3.8 0.52
RBBB 3.9 0.36
LBBB 3.6 0.36
NIL 3.9 0.45
VT HAS LOW MEAN SERUM POTASSIUM WHICH IS
STATISTICALLY SIGNIFICANT WITH P VALUE OF 0.001
3.7 3.7 3.9
2.7
3.8 3.9 3.6 3.9
MEAN POTASSIUM
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TYPE OF
ARRYTHMIA
SERUM POTASSIUM
LOW NORMAL
VPC 6 13
SINUS
TACHYCARDIA 7 14
CHB/1°/2° BLOCK 1 5
VT 17 2
SINUS
BRADYCARDIA 1 2
RBBB 0 3
LBBB 2 3*
NIL 4 20
6 7
1
17
1 0
2
4
13 1
4
5
2 2 3 3
20
TYPE OF ARRYTHMIA VS MG LEVEL
LOW NORMAL
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COMMON TYPE OF ARRYTHMIA IN AGE GROUP
AGE (IN
YEARS)
TOTAL NO OF
PTS
ARRTHYMIA
PRESENT
COMMON
TYPE
<40 9 4 LBBB(2)
41-50 23 17 VT(5)/VPC(5)
51-60 31 26 VPC(9)/VT(7)
61-70 25 18 ST(7)/VT(5)
>70 12 11 ST(5)
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TYPE OF ARRYTHMIA BASED ON SEX
TYPE OF
ARRYTHMIA
SEX
MALE FEMALE
VPC 19 0
SINUS
TACHYCARDIA 18 3
CHB/1°/2° BLOCK 6 0
VT 12 7
SINUS
BRADYCARDIA 2 1
RBBB 3 0
LBBB 4 1
NIL 19 5
AMONG MALE VPC IS MOST COMMON AND AMONG FEMALE
VT IS MOST COMMON
19 18
6
12
2 3
4
19
0
3
0
7
1 0 1
5
0
2
4
6
8
10
12
14
16
18
20
TYPE OF ARRYTHMIA VS SEX
MALE FEMALE
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TYPE OF MI
TYPE OF ARRYTHMIA AWMI (N=47)
VPC 14
SINUS TACHYCARDIA 8
CHB/1°/2° BLOCK 0
VT 12
SINUS BRADYCARDIA 0
RBBB 1
LBBB 4
NIL 8
VPC is the most common arrhythmia seen in patients with AWMI.
14
8
0
12
0
1
4
8
AWMI (N=47)
VPC
SINUS TACHYCARDIA
CHB/1°/2° BLOCK
VT
SINUS BRADYCARDIA
RBBB
LBBB
NIL
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TYPE OF
ARRYTHMIA
TYPE OF MI
ALMI
VPC 0
SINUS
TACHYCARDIA 2
CHB/1°/2° BLOCK 0
VT 0
SINUS
BRADYCARDIA 0
RBBB 0
LBBB 0
NIL 0
0%
100%
ALMI
SINUS TACHYCARDIA
64
TYPE OF
ARRYTHMIA
TYPE OF MI
ASMI
VPC 0
SINUS
TACHYCARDIA 5
CHB/1°/2° BLOCK 1
VT 1
SINUS
BRADYCARDIA 0
RBBB 0
LBBB 0
NIL 6
0
5
11
00
0
6
ASMI
SINUS TACHYCARDIA CHB/1°/2° BLOCK VT NIL
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TYPE OF
ARRYTHMIA
TYPE OF MI
IWMI
VPC 2
SINUS
TACHYCARDIA 5
CHB/1°/2° BLOCK 1
VT 1
SINUS
BRADYCARDIA 3
RBBB 1
LBBB 0
NIL 4
2
5
11
3
1
0
4
IWMI
VPC SINUS TACHYCARDIA CHB/1°/2° BLOCK
VT SINUS BRADYCARDIA RBBB
LBBB NIL
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TYPE OF
ARRYTHMIA
TYPE OF MI
PWMI/IWMI
VPC 2
SINUS
TACHYCARDIA 1
CHB/1°/2° BLOCK 4
VT 5
SINUS
BRADYCARDIA 0
RBBB 1
LBBB 1
NIL 5
HEART BLOCK IS PREDOMINANTLY SEEN IN PATIENTS WITH
INFERIOR WALL AND POSTERIOR WALL MI.
2 1
4
5
0
1
1
5
PWMI/IWMI
VPC SINUS TACHYCARDIA CHB/1°/2° BLOCK
VT SINUS BRADYCARDIA RBBB
LBBB NIL
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TYPE OF
ARRYTHMIA
TYPE OF MI
AWMI/IWMI
VPC 1
SINUS
TACHYCARDIA 0
CHB/1°/2° BLOCK 0
VT 0
SINUS
BRADYCARDIA 0
RBBB 0
LBBB 0
NIL 1
50%
0%
50%
AWMI/IWMI
VPC
SINUS TACHYCARDIA
CHB/1°/2° BLOCK
VT
SINUS BRADYCARDIA
RBBB
LBBB
NIL
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TREATMENT SERUM MAGNESIUMLOW NORMAL
DC
SHOCK/THROMBOLYSIS 13 7
THROMBOLYSIS ONLY 28 52
CHI SQUARE TEST
P VALUE-0.015
ODDS RATIO- 3.4
SIGNIFICANT
0
10
20
30
40
50
60
LOW NORMAL
13
7
28
52
TREATMENT VS MG LEVEL
DC SHOCK/THROMBOLYSIS THROMBOLYSIS ONLY
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TREATMENT SERUM MAGNESIUMMEAN STANDARD DEVIATION
DC
SHOCK/THROMBOLYSIS
1.47 0.43
THROMBOLYSIS ONLY 1.76 0.24
UNPAIRED T TEST
P -0.015
SIGNIFICANT
1.4
7
1.7
6
D C  SHOCK / THROMBOLY S I S THROMBOLY S I S  ONLY
MEAN SERUM MAGNESIUM
70
TREATMENT SERUM POTASSIUMLOW NORMAL
DC
SHOCK/THROMBOLYSIS
13 7
THROMBOLYSIS ONLY 28 52
CHI SQUARE TEST
P VALUE-0.001
ODDS RATIO- 15.92
SIGNIFICANT
13
7
28
52
0
10
20
30
40
50
60
LOW NORMAL
DC SHOCK/THROMBOLYSIS THROMBOLYSIS ONLY
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TREATMENT
SERUM POTASSIUM
MEAN STANDARDDEVIATION
DC
SHOCK/THROMBOLYSIS 2.77 0.56
THROMBOLYSIS ONLY 3.82 0.48
UNPAIRED T TEST
P -0.001
SIGNIFICANT
2.77
3.82
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
DC SHOCK/THROMBOLYSIS THROMBOLYSIS ONLY
MEAN POTASSIUM VS TREATMENT
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TYPE OF
ARRYTHMIA
TREATMENT
DC
SHOCK/THROMBOLYSIS
THROMBOLYSIS
ONLY
VPC 0 19
SINUS
TACHYCARDIA 0 21
CHB/1°/2° BLOCK 0 6
VT 19 0
SINUS
BRADYCARDIA 0 3
RBBB 1 2
LBBB 0 5
NIL 0 24
Out of 100 patients with Acute MI, 41 patients had low serum
magnesium levels of which 35 patients developed arrhythmias of which 13
patients developed ventricular tachycardia which was statistically significant
with p value 0.008.
0
5
10
15
20
25
30
TREATMENT VS TYPE
DCSHOCK/THROMBOLYSIS THROMBOLYSIS ONLY
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DISCUSSION
Strengths and weaknesses of the study design.
Strengths:
Defining the case:
The diagnosis of ST segment elevation Myocardial infarchon is very
simple.
Methods: This study needed only serum samples for the estimation of
magnesium and potassium which can be estimated relatively easier in central
laboratory. Arrhythmias are easily diagnosed by electrocardiogram and
continuous cardiac monitoring.
Confounding factors:
The study population is relatively homogenous. No patients had
previous history of CAD / Heart failure on Diuretics which would have an
effect on the result obtained. And also these patients are not presented with
ketoacidosis which would alter serum magnesium values.
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The objective nature of the result:
The results obtained are the concentration of serum magnesium and
serum potassium in acute MI patients. And arrhythmias are documented.
Questionnaires were not required. Thus the result is not influenced by the
subjective variation of either the patient or the examiner.
Weaknesses:
Small sample size:
The number of cases included in the study population was 100. The
study was done over a period of 18 months. It is highly difficulty to find out a
case of STEMI without the frequent co-morbidities like hypertension and
diabetes mellitus which also has an impact over the serum magnesium levels.
Since the number of sample is 100. It is non-representative of general
population.
The internal environment of the patient:
The samples were collected within 6 hours of admission into the
hospital. Though the time interval is relatively short, the internal environment
in a patient with acute myocardial infarction vary significantly over time due
to fluctuating catecholamine levels, thus affecting the magnesium content.
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Incidence of Reperfusion Arrhythmias:
Patients with STEMI are treated with fibrinolytic therapy in our
hospital. It is associated with varying incidence of reperfusion arrhythmias
which does not have a co-relation with magnesium and potassium levels. And
they are no definite criteria to establish reperfusion arrhythmias.
PREVIOUS STUDIES
Before discussing about the results obtained a brief review about the
results and conclusion of previous studies on this topic of serum magnesium
levels in acute myocardial infarction patients.
1. Serum magnesium in acute myocardial infarction: Actamedica
Scandinavia. Volume 206, Issue 1-6 pages 59-66, December 1980.
- Thomas Dyckner
During the one and a half years of the study, 342 patients with acute
myocardial infarction were treated at Serafimerlasarettet. The acute MI group
had significantly lower serum magnesium levels than a reference group. The
incidence of Ventricular ectopics, Ventricular tachycardia and Ventricular
fibrillation were significantly higher in the hypomagnesaemia patients.
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2. Magnesium and Acute Myocardial infarction. Transient
Hypomagnesaemia Not Induced by Renal magnesium Loss.
Arch Intern Med. 1986; 146(5) :872-874.
H. Sandvad Rasmussen, MD; P. Arup, MD; S. Hojberg, MD Blood and
urine samples were taken during the time of admission. Urine samples
were taken every 8 hours for the next 7 days. Both urine and blood
magnesium were analyzed. 13 patients were found to have MI.11 normal
people were taken as controls. The acute myocardial infarction patients had
significantly lower levels of serum magnesium. The urine concentration of
magnesium did not increase with time. This shows that the
hypomagnesaemia is not due to the renal loss magnesium. The mechanism
is due to a shift from the extracellular compartment, maybe due to
sequestration with the increased levels of free fatty acids.
3. Serum magnesium and potassium in Acute Myocardial Infarction
Arch intern Med. 1987; 147(3): 465- 469
-Henryk Kafka, MD; Lorrie Langevin, RN.
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Over a period of 13 months, serum magnesium and potassium levels were
measured in 590 patients admitted in a coronary care unit. Hypokalemia
occurred in 17% of the patients. However, hypomagnesaemia occurred in ten
of the thirteen patients with myocardial infarction and hypomagnesaemia.
However the mean levels of serum magnesium levels in the normal healthy
population was significantly higher than the reference levels. So the findings
in the study may not be applicable to outside population because of higher
magnesium content of soil in the selected study area of south eastern Ontario.
In the study conducted in our ICCU, the most common age group with
acute MI is 51-60 years (31%).  Anterior wall MI (47) is the most common
type followed by inferior and posterior wall MI (19). 76 % of the patients
developed arrhythmias. The most common type of arrhythmias are Sinus
tachycardia (21), ventricular ectopics (19) and ventricular tachycardia (19)
followed by bundle branch blocks (8), AV block (6) and sinus Bradycardia
(3).
Low serum magnesium levels and low potassium levels was observed
in 41% and 38% respectively.  The mean serum magnesium levels in sinus
tachycardia and ventricular ectopic is 1.77 mg/dl and 1.75 mg/dl respectively.
The mean serum magnesium levels in patients with ventricular tachycardia is
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1.44 mg/dl and mean serum potassium level is 2.7 meq/l which was
statistically significant p value 0.008
Hence it shows that low serum magnesium and potassium levels that
occurred in a patient with Acute MI developed life threatening ventricular
arrhythmias primarily ventricular tachycardia. This was in accordance with
the previous studies that were done in the past.
This opens to widespread discussion that whether prophylactic
intravenous magnesium or oral magnesium tablets are helpful in preventing
life threatening ventricular arrhythmias. Several clinical trials were conducted
on the prophylactic role of magnesium therapy, which are as follows
Intravenous magnesium sulphate in suspected acute myocardial
infarction: results of the second Leicester Intravenous Magnesium
Intervention Trial (LIMIT-2)
Lancet. 1992 Jun 27; 339(8809):1553-8
Here they conducted a randomized, double blind, placebo controlled
study in 2316 patients with suspected acute myocardial infarction who
received either intravenous magnesium sulphate (8 mmol over 5 min followed
by 65 mmol over 24 h) or physiological saline. The primary outcome measure
was 28-day mortality, which was ascertained in 99.3% of patients.
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The groups were well balanced for prognostic factors. By intention-to-treat
analysis mortality from all causes was 7.8% in the magnesium group and
10.3% in the placebo group (2p = 0.04), a relative reduction of 24% (95%
confidence interval 1-43%). Within the coronary care unit the incidence of left
ventricular failure was reduced by 25% (7-39%) in the magnesium group (2p
= 0.009).
The side-effects of magnesium treatment were transient flushing,
related to speed of injection of the loading dose, and an increased incidence of
Sinus Bradycardia.
There was a considerable enthusiasm for the routine use of intravenous
magnesium in patients with MI, based on the findings of the LIMIT 2 trail
which observed a 24 % reduction in mortality compared with placebo. The
larger ISIS 4 and MAGIC (magnesium in coronary arteries) failed to duplicate
this effect.
However, some have speculated that the lack of effect in ISIS 4 was
because of delayed administration or low control group mortality. In the
modern era, magnesium is not routinely used other than to replete serum
magnesium levels lower than 2.0 mcg/dl or for the management of torsade de
pointes.
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But this study conducted in our ICCU, Department of Cardiology there
is a positive correlation between low serum magnesium levels and ventricular
arrhythmias by which we would recommend for the early serum estimation of
magnesium and potassium levels and to replete it when low. The preferred
dose is 1 to 2 g IV over 5 minutes.  It also requires several large scale studies
to negate the weaknesses in ISIS 4 and MAGIC trails and to prove the
efficacy of prophylactic magnesium therapy.
81
SUMMARY
1. Most commonly patients with AMI were in the 6th decade.
2. Acute myocardial infarction is most commonly seen in males.
3. AWMI is the most common type of MI followed by IWMI with PWMI.
4. The most common type of arrhythmias in AMI are Sinus
tachycardia>ventricular ectopics >ventricular tachycardia.
5. Low serum magnesium levels and low potassium levels was observed
in 41% and 38% respectively.
6. The mean serum magnesium levels in patients with ventricular
tachycardia are 1.44 mg/dl and mean serum potassium level is 2.7 meq/l
which was statistically significant p value 0.008.
This shows that low magnesium and low potassium
occurring in patients with AMI leads to life threatening ventricular
arrhythmias.
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CONCLUSION
We conclude the magnesium levels do fall significantly in patients with
Acute Myocardial Infarction and low serum magnesium in these subset of
patients develop life threatening ventricular arrhythmias in the initial 48
hours.  Hence we recommend for the early estimation of serum magnesium
levels in patients with Acute MI and to replete it when low which would be
lifesaving. More such studies are needed especially with a bigger sample size
to find out the role and efficacy of prophylactic magnesium therapy.
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PROFORMA
NAME:
AGE:
SEX:
IP NO:
DATE OF ADMISSION:
DATE OF DISCHARGE:
PRESENTING COMPLAINTS:
CHEST PAIN
PALPITATION
SYNCOPE
DYSPNEOA
SWEATING/GIDDINESS
COMORBIDITIES:
TYPE2DM/SHT/BA/TB/CKD/CVA
VITALS:
BP:
PR:
SP02:
ECG (DAY 1, 2, 3):
CARDIAC BIOMARKERS:
CPK-MB:
SERUM MAGNESIUM:
SERUM POTASSIUM:
LFT:
RFT:
DIAGNOSIS:
TREATMENT FOR ARRYTHMIAS:
DC SHOCK/ANTI ARRYTHMIC DRUGS
ECHO:
CONDITION ON DISCHARGE:
NAME
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TREATMENT
SIMON RAJA 39 M STEMI/AWMI ? ? VT 1.5 2.2
PETCHIAMMAL 65 F STEMII/IWMI ? ? VT 1.3 2.5 DC SHOCK/THROMBOYLSIS
KUMARESAN 53 M STEMI/IWMI/PWMI ? ? VT 1.2 1.9 DC SHOCK/THROMBOYLSIS
BOOTHAPANDI 45 M STEMI/AWMI ? ? VT 1.9 3.1 DC SHOCK/THROMBOYLSIS
SUDALAIMADI 45 F STEMI/AWMI ? ? VT 0.7 2.4 DC SHOCK/THROMBOYLSIS
PERUMAL 70 M STEMI/AWMI ? ? VT, RBBB 1.7 2.4 DC SHOCK/THROMBOYLSIS
ARUMUGAM 52 M STEMI/IWMI/PWMI ? ? VT 1.6 2.9 DC SHOCK/THROMBOYLSIS
PAPPU 50 F STEMI/AWMI ? ? VT 1.7 2.3 DC SHOCK/THROMBOYLSIS
GANAPATHY 50 F STEMI/AWMI ? ? VT 0.9 2.9 DC SHOCK/THROMBOYLSIS
KASIPANDI 62 M STEMI/IWMI/PWMI ? ? VT 0.6 3.1 DC SHOCK/THROMBOYLSIS
60 M STEMI/AWMI ? ? RBBB,VT 2.1 3.6 DC SHOCK/THROMBOYLSIS
SUSILA 55 F STEMI/ASMI ? ? VT 2.3 3.4 DC SHOCK/THROMBOYLSIS
SUNDARAM 55 M STEMI/AWMI ? ? VT 1.1 2.5 DC SHOCK/THROMBOYLSIS
LAKSHMI 78 F STEMI/AWMI ? ? VT 2.1 3.9 DC SHOCK/THROMBOYLSIS
SHANUMAGA 70 F STEMI/IWMI/PWMI ? ? VT 1.3 2.6 DC SHOCK/THROMBOYLSIS
GANESAN 48 M STEMI/AWMI ? ? VT,RBBB 1.2 2.3 DC SHOCK/THROMBOYLSIS
MADASAMY 40 M STEMI/AWMI 120/80 70 LBBB 1.6 3.9 THROMBOLYSIS
SANKARAN 43 M STEMI/IWMI/PWMI 130/90 70
SINUS
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1.8 3.7 THROMBOLYSIS
BISMIBEGAM 48 F STEMI/AWMI 150/100 90 LBBB 2.1 4.1 THROMBOLYSIS
ESAKKIPANDI 50 M STEMI/EXT AWMI 140/90 90 LBBB 2 3.4 THROMBOLYSIS
GNANASELVAN 50 M STEMI/IWMI/PWMI 100/70 80 RBBB, CHB 2 3.8 THROMBOLYSIS/ATROPINE
SELVAM 35 M STEMI/AWMI 200/120 86 LBBB 1.4 3.2 THROMBOLYSIS
CHELLAPA 67 M STEMI/AWMI 110/70 118 VPC,ST 2.1 3.7 THROMBOLYSIS
SUBBAIAH 65 M STEMI/AWMI/IWMI 100/70 84 VPC 1.6 3.9 THROMBOLYSIS
SHANKARAN 65 M STEMI/IWMI/PWMI 90/60 60 VPC 1.5 3.3 THROMBOLYSIS
SHANMUGAIAH 53 M STEMI/AWMI 110/80 112 VPC, ST 1.7 3.5 THROMBOLYSIS
SUDALI 54 M STEMI/AWMI 130/80 124 VPC,ST 1.6 3.9 THROMBOLYSIS
RAJENDRAN 49 M STEMI/AWMI 120/80 90 VPC 2.1 4.2 THROMBOLYSIS
SUDALAI 55 M STEMI/AWMI 110/60 126 VPC, ST 3 4.6 THROMBOLYSIS
RAMACHANDRAN 55 M STEMI/AWMI 150/110 80 VPC 1.6 3.1 THROMBOLYSIS
JEYARAM 63 M STEMI/AWMI 160/100 90 VPC 2.1 3.9 THROMBOLYSIS
ANNAPOORANAM 74 M STEMI/AWMI 110/70 89 VPC 1.7 3.7 THROMBOLYSIS
SUNDARAM 55 M STEMI/IWMI/PWMI 100/80 128 VPC,ST 1.8 4.1 THROMBOLYSIS
THANGARAJ 56 M STEMI/IWMI 100/70 90 VPC 1.5 3.1 THROMBOLYSIS
MUTHUPANDI 51 M STEMI/IWMI 90/60 50 VPC 1.9 3 THROMBOLYSIS
JEYARAM 60 M STEMI/AWMI 180/100 96 VPC 1.4 2.9 THROMBOLYSIS
SUDALAI 48 M STEMI/AWMI 130/80 88 VPC 1.8 3.8 THROMBOLYSIS
ESAKKI 45 M STEMI/AWM 140/90 90 VPC 1.9 4.1 THROMBOLYSIS
RANGARAJ 45 M STEMI/AWMI 100/70 120 VPC, ST 1.8 4.9 THROMBOLYSIS
CHELLAPA 67 M STEMI/IWMI 90/60 70 NIL 1.5 3.2 THROMBOLYSIS
MANI 45 M STEMI/AWMI 100/70 89 NIL 1.7 3.8 THROMBOLYSIS
CHELLAIYA 51 M STEMI/IWMI 120/80 90 NIL 1.8 4.1 THROMBOLYSIS
RAMAMMAL 73 F STEMI/ASMI 120/70 88 NIL 1.4 3 THROMBOLYSIS
SURESH 39 M STEMI/ASMI 130/100 80 NIL 1.8 4 THROMBOLYSIS
SUNDARAM 43 M STEMI/AWMI 150/100 95 NIL 1.7 4.3 THROMBOLYSIS
MANIKKAM 60 M STEMI/AWMI 100/70 90 NIL 1.6 4.6 THROMBOLYSIS
SEYADRAHIYA 65 F IWMI/PWMI 90/60 50 NIL 1.8 4.4 THROMBOLYSIS
KASTURI 66 F STEMI/AWMI 100/70 78 NIL 1.5 3.4 THROMBOLYSIS
ESAKKIMUTHU 61 M STEMI/ASMI 120/80 88 NIL 1.9 4.2 THROMBOLYSIS
MADASAMY 26 m STEMI/ASMI 120/70 90 NIL 2.2 4.3 THROMBOLYSIS
MARIAPPAN 37 M STEMI/AWMI 140/90 98 NIL 2 3.9 THROMBOLYSIS
MUHAMMED 50 M STEMI/AWMI 130/80 80 NIL 2.3 4.5 THROMBOLYSIS
MEENAKSHI 47 F STEMI/ASMI 140/80 80 NIL 2.3 4.8 THROMBOLYSIS
GANAPATHY 66 M STEMI/IPWMI 80/50 60 NIL 2 4.3 THROMBOLYSIS
PAZHAIMUTHU 60 M STEMI/AWMI/IWMI 90/60 90 NIL 1.8 3.8 THROMBOLYSIS
LAKSHMANAN 50 M STEMI/ASMI 100/70 80 NIL 1.9 3.6 THROMBOLYSIS
MEENAKSHI 70 F STEMI/IWMI 90/60 90 NIL 1.9 4.1 THROMBOLYSIS
ANBALAGAN 32 M STEMI/IPWMI 100/70 90 NIL 1.8 3.8 THROMBOLYSIS
MADASAMY 50 M STEMI/IWMI/LWMI 80/60 56 NIL 1.8 3.7 THROMBOLYSIS
NALLAKNU 34 M STEMI/IWMI/PWMI 100/60 80 NIL 1.6 3.4 THROMBOLYSIS
PREMKUMAR 55 M STEMI/AWMI 120/80 79 NIL 1.8 4.2 THROMBOLYSIS
RAJAKANI 60 M STEMI/EXT AWMI 110/70 94 NIL 2.1 4.3 THROMBOLYSIS
ESWARAVEL 70 M STEMI/IWMI/PWMI 90/70 66 NIL 1.4 3.7 THROMBOLYSIS
SANKARAN 55 M STEMI/AWMI ? ? VT 1.3 2.6 DC SHOCK/THROMBOYLSIS
AMALA 67 M IWMI/PWMI ? ? VT 1.2 2.5 DC SHOCK/THROMBOYLSIS
GANESAN 55 M STEMI/AWMI ? ? VT 2.3 3.9 DC SHOCK/THROMBOYLSIS
HASSEN MYDEEEN 77 M STEMI/AWMI ? ? VT 1.5 2.4 DC SHOCK/THROMBOYLSIS
PONNAIAH 75 M STEMI/ASMI 100/70 87 I DEGREE HEARTBLOCK 1.8 4.7 THROMBOLYSIS
SHANMUGAVEL 70 M STEMI/IWMI/PWMI 100/60 80 2 DEGREE HEARTBLOCK 1.8 4.3 THROMBOLYSIS
MOORTHY 49 M STEMI/AWMI 100/60 85 VPC, I DEG HB 1.4 3.1 THROMBOLYSIS
GANESAN 55 M STEMI/IWMI 90/50 55 SB, I DEG HB 1.7 4.2 THROMBOLYSIS
SHIEK MOHAIDEEN 57 M STEMI/EXT AWMI 110/70 90 VPC, I DEG HB 1.5 3.5 THROMBOLYSIS
THNGASAMY 70 M STEMI/IWMI/PWMI 80/50 40 CHB 1.3 4 THROMBOLYSIS
AMIRTHARAJ 80 M STEMI/IWMI/RVMI 80/50 42 RBBB, CHB 1.5 4.3 THROMBOLYSIS
SETHURANI 50 F STEMI/IWMI 90/60 50 SB, I DEG HB 1.6 4 THROMBOLYSIS
MAHESHWARAN 78 M STEMI/ILMI 100/70 54 2 DEGREE HEARTBLOCK 1.5 3.5 THROMBOLYSIS
SAMY DHAS 51 M STEMI/IWMI 90/60 52 SB 1.5 3.2 THROMBOLYSIS
JAMAL MYDEEN 36 M STEMI/IWMI/PWMI 90/50 50 SB,CHB 1.8 4.1 THROMBOLYSIS
SHEIK MYDEEN 51 M STEMI/IWMI/PWMI 80/50 44 CHB 1.6 3.3 THROMBOLYSIS
KANDASMAMY 52 M STEMI/AWMI 100/70 110 ST 1.5 3.2 THROMBOLYSIS
RAMACHANDRAN 70 M STEMI/ASMI 110/70 120 ST 1.7 3.1 THROMBOLYSIS
ASHAN MYDEEN 65 M STEMI/ALMI 120/80 112 ST 1.5 3.2 THROMBOLYSIS
SORNAMMAL 75 F STEMI/IWMI/PWMI 110/70 110 ST 1.6 3.4 THROMBOLYSIS
MAHADEVI 55 F STEMI/ASMI 100/70 106 ST 1.9 3.9 THROMBOLYSIS
SATHAR 60 M STEMI/AWMI 110/70 110 ST 1.9 4.1 THROMBOLYSIS
RATHINAM 55 M STEMI/IWMI 100/70 108 ST 2.1 4.3 THROMBOLYSIS
MOHANRAJ 64 M STEMI/AWMI 110/70 116 ST 1.5 3.2 THROMBOLYSIS
PAULRAJ 74 M STEMI/IWMI 100/70 114 ST 1.5 3.1 THROMBOLYSIS
VADIVEL 60 M STEMI/ASMI 110/70 106 ST 1.9 4 THROMBOLYSIS
SAKTHIVEL 71 M STEMI/ASMI 120/80 126 ST 2.1 4.6 THROMBOLYSIS
RASAIAH 65 M STEMI/AWMI 110/70 120 ST 1.8 3.9 THROMBOLYSIS
RAJA 58 M STEMI/IWMI 90/60 112 ST 1.7 3.9 THROMBOLYSIS
ARUNACHALAM 62 M STEMI/AWMI 110/70 116 ST 1.7 4 THROMBOLYSIS
MARIAPPAN 50 M STEMI/IWMI 100/60 102 ST 1.8 4 THROMBOLYSIS
SHANMUGAVEL 46 M STEMI/AWMI 120/80 112 ST 1.9 4 THROMBOLYSIS
MAHALINGAM 70 M STEMI/ALMI 130/80 140 ST 1.5 3 THROMBOLYSIS
DEVANAYAGAM 52 M STEMI/AWMI 120/70 124 ST 1.8 4 THROMBOLYSIS
MARIAPPAN 70 M STEMI/IWMI 100/60 120 ST 2 4 THROMBOLYSIS
GURUSAMY 75 M STEMI/AWMI 120/80 112 ST 1.7 3.7 THROMBOLYSIS
ESAKKIYAMMAL 75 F STEMI/ASMI 100/60 124 ST 3.1 4.3 THROMBOLYSIS
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ABBREVIATIONS
STEMI: ST segment Elevation Myocardial Infarction
IHD: Ischemic Heart Disease
AMI: Acute Myocardial Infarction
UA: Unstable Angina
ECG: Electrocardiogram
CK: Creatinine Kinase
rPA: Reteplase
tPA: tissue Plasminogen Activator
CABG: Coronary Artery Bypass Graft
PCI: Percutaneous Coronary Intervention
ACE: Angiotensin Converting Enzyme
RCA: Right Coronary Artery
AIVR: Accelerated Idioventricular Rhythm
RAAS: Renin Angiotensin Activating System
EAD: Early After Depolarisation
DAD: Delayed After Depolarisation
ISE: Ion Sensitive Electrode
AWMI: Extensive Anterior Wall Myocardial Infarction
ALMI: Antero Lateral Myocardial Infarction
ASMI: Antero Septal Myocardial Infarction
IWMI/PWMI: Infero Posterior Wall Myocardial Infarction
VPC: Ventricular Premature Complex
VT: Ventricular Tachycardia
RBBB: Right Bundle Branch Block
LBBB: Left Bundle Branch Block
CHB: Complete Heart Block
DC: Direct Cardioversion
